Assessment of vocation of rifabutin and rifapentine in replace of rifampcin in drug resistance leprosy patients: a molecular simulation study

Document Type : Original article


1 Microbiology and Molecular Biology National JALMA Institute for Leprosy and Other Mycobacterial Diseases Agra, India

2 Medical Division National JALMA Institute for Leprosy and Other Mycobacterial Diseases Agra, India

3 National JALMA Institute for Leprosy and Other Mycobacterial Diseases Agra, India


The emergence of drug resistance in leprosy is a major hurdle in leprosy elimination programme. Although the problem of drug resistance is presently not acute, it is important that we collect data more systematically and monitor the trend carefully so that effective measures to combat this problem can be developed. The present study aimed at the explication of cross resistance of rifabutin and rifapentine to rifampicin which would be helpful to programme managers for implementing rifabutin or rifapentine in replace of rifampicin. In this study we built 3D model of the M. leprae rpoB using Swiss Model and the modelled structure was docked with rifampicin, rifabutin and rifapentine. We established that these 3 antibiotics interact with the same binding region in the modelled rpoB of M. leprae. Thus we conclude that vocation of rifabutin and rifapentine could not be suitable in replace of rifampicin to combat with drug resistance leprosy.


1. Guinto RS, Cellona RV, Fajardo TT, de Cruz EC.  Primary dapsone-resistant leprosy in Cebu, Philippines. Int J Lepr Other Mycobact Dis 1981;49:427-430.
2. de  La  Cruz  E, Cellona  RV,  Balagon  MVF, Villahermosa LG, Fajardo TT Jr, Abalos RM, Tan EV, Walsh GP.  Primary dapsone resistance in Cebu, The Philippines; cause for concern.  Int J Lepr Other Mycobact Dis 1996;64:253-256.
3. Browne SG, Hogerzeil LM. “B 663” in the treatment of leprosy. Preliminary report of a pilot trial. Lepr Rev 1962;33:6-10.
4. Levy GH, Shepard CC, Fasal P.  The bactericidal effect of rifampicin on M leprae in man: a) single doses of 600, 900 and 1,200 mg, and b) daily doses of 300 mg. Int J Lepr 1976;44:183-187.
5. Grosset JH, Guelpa-Lauras CC, Bobin P, Brucker G, Cartel JL, Constant-Desportes M, Flageul B, Frederic M, Guillaume JC, Millan J. Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin. Int J Lepr Other Mycobact Dis 1989;57:607-614.
6. Pettit JHS and Rees RJW. Sulphone resistance in leprosy. An experimental and clinical study. Lancet 1964;2:673-674.
7. Maeda S, Matsuoka M, Nakata N, Nakata N, Kai M, Maeda Y, Hashimoto K, Kimura H, Kobayashi K, Kashiwabara Y. Multidrug Resistant Mycobacterium leprae from Patients with Leprosy. Antimicrob Agents Chemother 2001;45:3635-3639.
8. Diorio SM, Rosa PS, Belone AFF,Sartori BGC, Trino LM, Baptista IMFD, Marcos EVC, Barreto JA, Ura S. Relapse related to drug resistance in leprosy. Hansen Int 2009;34:43-48.
9. Matsuoka M, Suzuki Y, Garcia IE, Fafutis-Morris M, Vargas-González A, Carreño-Martinez C, Fukushima Y, Nakajima C. Possible mode of emergence for drug– resistant leprosy is revealed by an analysis of samples from Mexico. Jpn J Infect Dis 2010;63:412-416.
10. Sekar B, Arunagiri K, Kumar BN, Narayanan S, Menaka K, Oommen PK. Detection of mutations in folp1, rpoB and gyrA genes of M. leprae by PCR- direct sequencing- A rapid tool for screening drug resistance in leprosy. Lepr Rev 2011;82:36-45.
11. Kai M, Phuc NHN, Nguyen HA, Pham TH, Nguyen KH, Miyamoto Y, Maeda Y, Fukutomi Y, Nakata N, Matsuoka M, Makino M, Nguyen TT. Analysis of drug-resistant strains of Mycobacterium leprae in an endemic area of Vietnam. Clin Infect Dis 2011;52:127-132.
12. Wahyuni R, Adriati D, Iswahyudi I, Prakoeswa CRS, Agusni I, Izumi S. Profile of mutation on drug resistance Mycobacterium leprae isolates in Indonesia collected during 2003-2011. Microbiol 2012;6:135-138.
13. Zdobnov EM, Apweiler R. InterProScan—an integration platform for the signature-recognition methods in InterPro. Bioinformatics 2001;17:847–848.
14. Finn RD, Mistry J, Tate J, Coggill P, Heger A, Pollington JE, Gavin OL, Gunaseka-ran P, Ceric G, Forslund K, Holm L, Sonnhammer EL, Eddy SR, Bateman A. The Pfam protein families database. Nucleic Acids Res 2010;38:211-222.
15. Letunic I, Doerks T, Bork P. SMART 7: recent updates to the protein domain annotation resource. Nucleic Acids Res 2012;40:302-305.
16. Marchler-Bauer A, Anderson JB, Chitsaz F, Derbyshire MK, De Weese-Scott C, Fong JH, Geer LY, Geer RC, Gonzales NR, Gwadz M, He S, Hurwitz DI, Jackson JD, Ke Z, Lanczycki CJ, Liebert CA, Liu C, Lu F, Lu S, Marchler GH, Mullokandov M, Song JS, Tasneem A, Thanki N, Yamashita RA, Zhang D, Zhang N, Bryant SH. CDD: specific functional annotation with the conserved domain database. Nucleic Acids Res 2009;37:205-210.
17. Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, Keifer F, Gallo Cassarino T, Bertoni M, Bordoli M, Bordoli L, Schwede T. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 2014;42:252-258.
18. Laskowski RA, Watson JD, Thornton JM. ProFunc: a server for predicting protein function from 3D structure. Nucleic Acids Res 2005;33:W89–W93
19. Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci 1993;2:1511-519.
20. Vriend G. WHAT IF: a molecular modeling and drug design program. J Mol Graph 1990;8:52-56.
21. Wiederstein M, Sippl MJ. ProSA-web: Interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res 2007;35:407-410.
22. Anand P, Nagarajan D, Mukherjee S, Chandra N. PLIC: protein–ligand interaction clusters. Database 2014;2014: Doi 10.1093/database/bau029
23. Labbe CM, Rey J, Lagorce D, Vavrusa M, Becot, J, Sperandio O, Villoutreix BO, Tuffery P, Miteva MA. MTiOpenScreen: a web server for structure-based virtual screening. Nucleic Acids Res 2015;43:448-54.
24. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J Comput Chem 2009;16:2785-2791.
25. World Health organization. Epidemiological situation, burden and distribution. 2015;Accessed on 29.02.2017.
26. Manglani PR, Arif MA. Multidrug therapy in leprosy. J Indian Med Assoc2006; 104:686-688.
27.Wolcott RR, Ross H. Exacerbation of leprosy during present day treatment. Int J Lepr 1953;21:437-440.
28. Jacobson RR, Hastings RC. Rifampin-resistant leprosy. Lancet 1976;2:1304–1305.
29. Kumar A, Girdhar A, Chakma JK, Girdhar BK. WHO multidrug therapy for leprosy: epidemiology of default in treatment in Agra district, Uttar Pradesh. India BioMed Res Int 2015;
30. Kaimal S, Thappa DM.  Relapse in leprosy. Indian J Dermatol Venereol Leprol 2009;75:126-135.
31. Williams DL, Gillis TP. Drug-resistant leprosy: monitoring and current status. Lepr Rev 2012;83:269-281.
32. Lavania M, Jadhav RS, Chaitanya VS, Turankar RP, Selvasekhar A, Das L, Dariong F, Hambroom UK, Kumar S, Sengupta U. Drug resistance patterns in Mycobacter-ium leprae isolates from relapsed leprosy patients attending The Leprosy Mission (TLM) Hospitals in India. Lepr Rev 2014;85:177-185.
33. Hasanoor Reja AH, Biswas N, Biswas S, Lavania M, Chaitanya VS, Banerjee S, Maha Patra PS, Gupta UD, Patra PK, Sengupta U, Bhattacharya B. Report of rpoB mutation in clinically suspected cases of drug resistant leprosy: a study from Eastern India. Indian J Dermatol Venereol Leprol 2015;81:155-161.
34. Mohanty PS, Mishra S, Naaz F, Chauhan DS, Arora M, Sagar S Bansal AK, Gupta UD. Rifampicin resistance in leprosy: Mutational analysis of rpoB gene. Int J Sci Nat 2015;6:641-644.
35. Yoder LJ, Guitrau M, Jacobson R. Comparison of a urine spot test and blood tests as indicators of patient compliance. Indian J Lepr 1991;63:195-202.
36. Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis 1996;22:15–21.
37. Dhople AM, Williams SL. The activity of rifabutin against Mycobacterium leprae in armadillos. Int J Antimicrob Agents 1997;9:169-173.
38. Prasad PV, Kaviarasan PK. Leprosy therapy, past and present: can we hope to eliminate it? Indian J Dermatol 2010;55:316–324
39. Consigny S. Bactericidal activities of HMR 3647, moxifloxicin and rifapentines against Mycobacterium leprae in mice. Antimicrob Agents Chemother 2000;44: 2919-2921.
40. Kwobah CM, Wools-Kaloustian KK, Gitau JN, Siika AM. Human immunode-ficiency virus and leprosy coinfection: Challenges in resource-limited setups. Case Rep Med 2012; Doi